130 related articles for article (PubMed ID: 25511624)
21. Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study.
Rizk E; Wilson AD; Murillo MU; Putney DR
Ther Drug Monit; 2018 Feb; 40(1):151-155. PubMed ID: 29120972
[TBL] [Abstract][Full Text] [Related]
22. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery.
Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM
J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361
[TBL] [Abstract][Full Text] [Related]
23. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy.
Kiser TH; MacLaren R; Fish DN; Hassell KL; Teitelbaum I
Pharmacotherapy; 2010 Nov; 30(11):1117-26. PubMed ID: 20973685
[TBL] [Abstract][Full Text] [Related]
24. Renal replacement therapy and anticoagulation.
Brandenburger T; Dimski T; Slowinski T; Kindgen-Milles D
Best Pract Res Clin Anaesthesiol; 2017 Sep; 31(3):387-401. PubMed ID: 29248145
[TBL] [Abstract][Full Text] [Related]
25. The use of the activated clotting time for monitoring heparin therapy in critically ill patients.
De Waele JJ; Van Cauwenberghe S; Hoste E; Benoit D; Colardyn F
Intensive Care Med; 2003 Feb; 29(2):325-8. PubMed ID: 12594595
[TBL] [Abstract][Full Text] [Related]
26. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
[No Abstract] [Full Text] [Related]
27. An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis.
Skagerlind MSE; Stegmayr BG
Eur J Clin Pharmacol; 2018 Mar; 74(3):267-274. PubMed ID: 29198062
[TBL] [Abstract][Full Text] [Related]
28. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
29. Incidence and risk factors for PTT prolongation in patients receiving low-dose unfractionated heparin thromboprophylaxis.
Feinbloom D; Freed JA; Carbo A; Jung Y; Adra M; Herzig SJ
J Thromb Thrombolysis; 2021 Jul; 52(1):331-337. PubMed ID: 33006065
[TBL] [Abstract][Full Text] [Related]
30. Continuous venovenous hemofiltration without anticoagulation.
Uchino S; Fealy N; Baldwin I; Morimatsu H; Bellomo R
ASAIO J; 2004; 50(1):76-80. PubMed ID: 14763495
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI.
Kikkert WJ; van Nes SH; Lieve KV; Dangas GD; van Straalen J; Vis M; Baan J; Koch KT; de Winter RJ; Piek JJ; Tijssen JG; Henriques JP
Thromb Haemost; 2013 May; 109(5):961-70. PubMed ID: 23446910
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of heparin dosing based on adjusted body weight in obese patients.
Fan J; John B; Tesdal E
Am J Health Syst Pharm; 2016 Oct; 73(19):1512-22. PubMed ID: 27646813
[TBL] [Abstract][Full Text] [Related]
33. Bleeding Risks in Patients on Percutaneous Ventricular Assist Devices Receiving Two Different Dextrose Concentrations of Heparinized Purge Solution: A Case Series.
Dietrich JN; Kazmi H
J Pharm Pract; 2019 Aug; 32(4):464-469. PubMed ID: 29439593
[TBL] [Abstract][Full Text] [Related]
34. Activated partial thromboplastin time (aPTT) monitoring to achieve therapeutic anticoagulation before and after introducing a nomogram for adjunctive heparin treatment with thrombolytic therapy for acute myocardial infarction.
Chamuleau SA; de Winter RJ
Int J Cardiol; 1998 Dec; 67(3):241-6. PubMed ID: 9894705
[TBL] [Abstract][Full Text] [Related]
35. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
[TBL] [Abstract][Full Text] [Related]
36. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials.
Wu MY; Hsu YH; Bai CH; Lin YF; Wu CH; Tam KW
Am J Kidney Dis; 2012 Jun; 59(6):810-8. PubMed ID: 22226564
[TBL] [Abstract][Full Text] [Related]
37. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of unfractionated heparin in critically ill patients.
Aarab R; van Es J; de Pont AC; Vroom MB; Middeldorp S
Neth J Med; 2013 Nov; 71(9):466-71. PubMed ID: 24218420
[TBL] [Abstract][Full Text] [Related]
39. Regional citrate anticoagulation for continuous renal replacement therapy in children.
Rico MP; Fernández Sarmiento J; Rojas Velasquez AM; González Chaparro LS; Gastelbondo Amaya R; Mulett Hoyos H; Tibaduiza D; Quintero Gómez AM
Pediatr Nephrol; 2017 Apr; 32(4):703-711. PubMed ID: 27896442
[TBL] [Abstract][Full Text] [Related]
40. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
